Targeted Alpha Therapy of mCRPC with 225Actinium-PSMA-617: Swimmer-Plot analysis suggests efficacy regarding duration of tumor-control

The aim of this evaluation is to identify first indicators regarding the efficacy of 225Ac-PSMA-617 therapy in a retrospectively analyzed group of patients. Methods: Forty patients with metastatic castration-resistant prostate cancer were selected for treatment with 3 cycles of 100 kBq/kgBW 225Ac-PSMA-617 in 2 months intervals. Prostate-specific antigen (PSA) and blood cell count were measured every 4 weeks. Prostate-specific membrane antigen (PSMA)-PET/CT or PSMA-SPECT/CT were used for baseline staging and imaging follow-up at month six. Follow-up included duration of PSA-response and radiological progression free survival at month six. Patient histories were reviewed for the duration of previous treatment lines and a Swimmer-Plot was used to intra-individually compare the duration of tumor control by PSMA-therapy vs. prior treatment modalities. Results: 31 of 40 patients were treated per protocol. 5 patients discontinued due to non-response, 4 patients due to xerostomia. In patients surviving at least eight weeks, a PSA decline >50% was observed in 24/38 (63%) and any PSA response in 33/38 (87%) of patients. Median duration of tumor-control under 225Ac-PSMA-617 last-line therapy was 9.0 months; 5 patients presented with enduring responses of > 2 years. As all patients had very advanced disease this compares favorably with the tumor-control rates associated with earlier phase disease; the most common preceding 1st, 2nd, 3rd and 4th line therapies were abiraterone (median duration 10.0 months), docetaxel (6.5 months), enzalutamide (6.5 months) and cabazitaxel (6.0 months). Conclusion: Positive response of surrogate parameters demonstrates remarkable anti-tumor activity of 225Actinium-PSMA-617. Swimmer-plot analysis indicates promising duration of tumor-control, especially taking into account the unfavorable prognostic profile of the selected advanced-stage patients. Xerostomia was the main reason to discontinue therapy or to refuse additional administrations and was in the same dimension as non-response; this indicates that further modifications of the treatment regimen with regard to side effects might be necessary to further enhance the therapeutic range.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2018 Jan 11 [Epub ahead of print]

Clemens Kratochwil, Frank Bruchertseifer, Hendrik Rathke, Markus Hohenfellner, Frederik L Giesel, Uwe Haberkorn, Alfred Morgenstern

University Hospital Heidelberg, Germany., European Commission, Joint Research Centre.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe